About Merck

Merck & Co., Inc. is a global research-driven pharmaceutical company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures.

Merck Announces Voluntary Worldwide Withdrawal of VIOXX®

WHITEHOUSE STATION, N.J., Sept. 30, 2004—Merck & Co., Inc. today announced a voluntary worldwide withdrawal of VIOXX® (rofecoxib), its arthritis and acute pain medication. The company’s decision, which is effective immediately, is based on new, three-year data from a prospective, randomized, placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on VIOXX) trial. A study showed it caused increased risk of heart attack and stroke.

The trial, which is being stopped, was designed to evaluate the efficacy of VIOXX 25 mg in preventing recurrence of colorectal polyps in patients with a history of colorectal adenomas. In this study, there was an increased relative risk for confirmed cardiovascular events, such as heart attack and stroke, beginning after 18 months of treatment in the patients taking VIOXX compared to those taking placebo. The results for the first 18 months of the APPROVe study did not show any increased risk of confirmed cardiovascular events on VIOXX, and in this respect, are similar to the results of two placebo-controlled studies described in the current U.S. labeling for VIOXX.

“We are taking this action because we believe it best serves the interests of patients,” said Raymond V. Gilmartin, chairman, president and chief executive officer of Merck. “Although we believe it would have been possible to continue to market VIOXX with labeling that would incorporate these new data, given the availability of alternative therapies, and the questions raised by the data, we concluded that a voluntary withdrawal is the responsible course to take.”

VIOXX SIDE EFFECTS

Vioxx has been linked to increased risk of heart attack, stroke, sudden cardiac death and more. Side effects of Vioxx can include diarrhea, nausea and heartburn, but many patients may not associate these effects with the use of Vioxx. Merck has removed Vioxx after and and extended study showed that patients using Vioxx double their risk of having a heart attack, stroke or other cardiovascular injury


REFUND FOR UNUSED VIOXX® (rofecoxib)

If you are a patient who took VIOXX, you may be eligible to receive a refund for the amount you paid out-of-pocket for VIOXX that remained unused as of September 30, 2004. Merck strongly recommends that you return any unused VIOXX to the National Notification Center (NNC) in accordance with the instructions below. However, if you have already destroyed or disposed of your unused VIOXX, or cannot return it in its original container, you may still be eligible to receive a refund under new procedures adopted by Merck.

To receive a refund for the amount you paid out-of-pocket for VIOXX that remained unused as of September 30, 2004, please call the National Notification Center (NNC) at 1-800-805-9542

You must submit a valid pharmacy receipt indicating that the prescription was dispensed:

On or after August 1, 2004, for a 30-day supply of 12.5-mg or 25-mg VIOXX

On or after June 1, 2004, for any amount greater than a 30-day supply of 12.5-mg or 25-mg VIOXX On or after June 1, 2004, for any amount of 50-mg VIOXX


UPDATE

February 17, 2004 within hours of congressional passage of the bill limiting class action lawsuits that directly affects the drug companys, the makers of Vioxx announced it would bring Vioxx back onto the market.


VIOXX CLASS ACTION LAWSUIT

The law firms featured at the top of the page can assist you with filing your claim in the Vioxx Class Action Lawsuit